Company news
Rani Therapeutics Holdings, Inc. news in 2026
Rani Therapeutics Holdings, Inc.'s news releases, calls and decks from 2026, newest first.
Rani Therapeutics Reports Third Quarter 2026 Financial Results; Provides Corporate Update
November 9, 2026
Rani Therapeutics to Participate in the Chardan Healthcare Conference
October 13, 2026
Rani Therapeutics Announces Acceptance into U.S. FDA's Emerging Technology Program (ETP)
October 5, 2026
Rani Therapeutics to Participate in Upcoming September Conferences
September 8, 2026
Rani Therapeutics Reports Second Quarter 2026 Financial Results; Provides Corporate Update
August 13, 2026
Rani Therapeutics Appoints Michelle Gilson to Board of Directors
August 4, 2026
Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
July 20, 2026
Rani Therapeutics Announces Positive Initial Phase 1a Data for RT-114 for the Treatment of Obesity, with Oral Bioavailability Exceeding Matched Subcutaneous Dosing
July 15, 2026
Rani Therapeutics Announces Research and Development Collaboration with PegBio to Expand Obesity Pipeline Across Multiple Novel Candidates
July 9, 2026
Rani Therapeutics Appoints Nicholas Maestas as Chief Financial Officer
June 29, 2026
Rani Therapeutics Holdings, Inc. Announces Pricing of $20.0 Million Registered Direct Offering of Class A Common Stock Priced At-The-Market Under Nasdaq Rules
May 26, 2026
Rani Therapeutics Reports First Quarter 2026 Financial Results; Provides Corporate Update; Announces CFO Transition
May 15, 2026
Rani Therapeutics to Participate in the H.C. Wainwright Annual BioConnect Investor Conference
May 12, 2026
Rani Therapeutics Appoints Dr. Sara Kenkare-Mitra as Strategic Advisor to Advance Platform and Clinical Strategy
April 8, 2026
Rani Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Corporate Update
March 25, 2026
Rani Therapeutics Appoints Jesper Høiland as Head of Strategy to Advance Corporate and Pipeline Prioritization
March 24, 2026
Rani Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results
March 19, 2026
Rani Therapeutics Announces the Promotion of Alireza Javadi, Ph.D. to Chief Technical Officer
January 28, 2026
Rani Therapeutics Initiates Phase 1 Study of RT-114 RaniPill® for the Treatment of Obesity in Collaboration with ProGen
January 8, 2026
Calls in 2026
Decks in 2026
- Investor Presentation (July 2026)
Investor deck · 34 slides · July 2026